Document and Entity Information - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2021

Mar. 15, 2022

Sep. 17, 2021

Cover [Abstract]

Document Type

10-K

Amendment Flag

false

Document Period End Date

Dec. 31, 2021

Document Fiscal Year Focus

2021

Document Fiscal Period Focus

FY

Current Fiscal Year End Date

--12-31

Entity Central Index Key

0001645569

Entity File Number

001-40794

Entity Registrant Name

DICE THERAPEUTICS, INC.

Entity Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity Voluntary Filers

No

Entity Well-known Seasoned Issuer

No

Entity Filer Category

Non-accelerated Filer

Entity Small Business

true

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

Entity Shell Company

false

Entity Tax Identification Number

47-2286244

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

279 E. Grand Avenue

Entity Address, Address Line Two

Suite 300

Entity Address, City or Town

South San Francisco

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

94080

City Area Code

650

Local Phone Number

566-1420

Entity Common Stock, Shares Outstanding

38,231,415

Entity Public Float

$ 978

Document Annual Report

true

Document Transition Report

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Security Exchange Name

NASDAQ

Trading Symbol

DICE

ICFR Auditor Attestation Flag

false

Auditor Name

Ernst & Young LLP

Auditor Firm ID

42

Auditor Location

New York, New York USA

Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s Definitive Proxy Statement relating to the Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Report.